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Abstract
Background: Reported data indicate that cancer cells have increased rates of glucose metabolism,
as determined by 18FDG-PET imaging in patients with malignancies. The results of many studies
have demonstrated that the expression of glucose transporters, especially Glut-1, is increased in a
variety of malignancies. This study was undertaken to assess the differential expression of Glut-1
and Glut-3 by benign and malignant melanocytic lesions.
Methods:  Immunohistochemical staining for Glut-1 and Glut-3 was performed on paraffin-
embedded tissue sections prepared from melanocytic nevi (12 cases), Spitz nevi (12 cases) and
primary cutaneous malignant melanomas (20 cases).
Results: We observed immunoreactivity for Glut-1 in all melanocytic nevi, 9 of the 12 Spitz nevi
and in 9 of the 20 malignant melanomas, whereas Glut-3 was expressed in all the melanocytic
lesions, both benign and malignant.
Conclusion: These findings indicate that the glucose transporters Glut-1 and Glut-3 play a role in
the glucose metabolism of melanocytic cells. Glut-1 was present in the majority of benign nevi,
whereas its expression was downregulated in 55% of malignant melanomas. Our results suggest
that glucose transporter Glut-1 expression can significantly discriminate between human malignant
melanoma and benign melanocytic nevi, and support the idea that additional mechanisms other than
Glut-1 may contribute to glucose uptake in melanomas.
Background
Glucose transporters (Glut-1-14) belong to a family of
structurally-related proteins that mediate energy-inde-
pendent glucose transport across the plasma membrane.
These transporters differ in their tissue distribution and
affinity for glucose [1,2]. Glut-1 was the first member of
the facilitated glucose transporter family identified [1]. It
is mostly expressed in erythrocytes, endothelial cells of the
blood-brain barrier and placental cells [3]. The human
Glut-1 gene, which has been localized to the short arm of
chromosome 1 (1p34.2), is 35 kb in length and contains
10 exons that encode a protein of 492 aminoacids. This
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protein is highly conserved among different species that
include human, rat, mouse and pig [4].
There is evidence that human malignancies, in which glu-
cose metabolism is increased, express higher levels of
Glut-1 than do normal cells. In particular, human Glut-1
is overexpressed in malignant cells and in a variety of
tumours, that include the breast, pancreas, cervix,
endometrium, lung, mesothelium, colon, bladder, thy-
roid, bone, soft tissues, and oral cavity [3,5-14]. Specifi-
cally, Glut-1 expression has been associated with
increased malignant potential, invasiveness, and a poor
prognosis [6,9,14,15]. Glut-3 is also expressed in human
malignant tissue, but there are discrepancies among the
reported results [9,16,17]. To the best of our knowledge,
immunoreactivity of Glut-1 has not previously been
shown for melanocytic lesions, and immunoreactivity for
Glut-3 has not been investigated on these lesions [18]. We
used immunohistochemistry to evaluate the expression of
Glut-1 and Glut-3 in human benign nevi and malignant
melanomas.
Methods
Tissue samples
We selected, retrospectively, 44 specimens from patients
who had undergone surgery for either benign or malig-
nant melanocytic lesions. The project was approved by the
Committee of Ethics at the Catholic University "Sacro
Cuore", Faculty of Medicine, Rome, Italy. Cases were
retrieved from the archives of the Pathology Laboratory,
Columbus Clinic, Catholic University "Sacro Cuore"
(Rome, Italy). The histological diagnoses were as follows:
melanocytic nevus, n = 12; Spitz nevus, n = 12; and pri-
mary cutaneous malignant melanoma, n = 20. The
patients with melanomas were subdivided into two
groups: the first contained ten patients whose tumour
thickness was less than or equal to 1 mm, whereas the sec-
ond contained ten patients whose tumour thickness was
more than 1 mm. All diagnoses had been made on the
basis of histopathological features that were evident in
sections routinely stained with haematoxylin and eosin.
The criterion for lesion selection was the almost absence
or paucity of melanin to allow a good immunohisto-
chemical evaluation. Table 1 summarizes the clinical and
pathological characteristics of the patients who were
affected by malignant melanomas. A sentinel lymph node
biopsy was performed on all patients with melanoma.
Immunohistochemistry
Immunohistochemical analysis was performed on 4 μm
paraffin sections of the tumours using an automatic
immunostainer (BenchMark; Ventana Medical Systems,
Tucson, AZ, USA). The sections were incubated for 24 min
at 37°C with a rabbit polyclonal antibody against Glut-1
(1:200; Diapath, Bergamo, Italy) and a rabbit monoclonal
antibody against Glut-3 (1:1000; Diapath). The immu-
nostaining was visualized using Xt Ultra View Red (Diap-
ath) as a chromogen, according to the manufacturer's
instructions. Cell nuclei were lightly counterstained with
standard Mayer's haematoxylin. Erythrocytes and kerati-
Table 1: Clinical and pathological findings of the patients affected by malignant melanoma
Patient n. Age Sex Site Thickness (mm) S-LFN LFN
Thickness ≤ 1 mm
1. 58 F Groin 0.7 -
2. 34 F Thigh 0.3 - -
3. 41 M Underscapular 0.88 -
4. 32 M Costal 0.4 -
5. 50 M Upperscapular 0.3 - +
6. 34 F Back 0.5 + (itc) -
7. 66 M Lumbar 0.5 + (itc) -
8. 64 M Paravertebral 0.5 -
9. 63 F Leg 1 -
10. 70 M Thorax 0.5 -
Thickness > 1 mm
1. 36 F Thigh 1.2 -
2. 55 F Knee 1.2 -
3. 31 M Back 1.4 + (itc) -
4. 63 F Forearm 1.1 -
5. 35 F Thigh 2 + -
6. 30 F Thigh 1.7 -
7. 33 M Arm 1.4 -
8. 62 F Arm 3 -
9. 38 F Pubis 2.7 + -
10. 59 F Leg 2 -
S-LFN, sentinel lymph node; LFN, regional lymphadenectomy; itc, isolated tumour cellsJournal of Experimental & Clinical Cancer Research 2008, 27:34 http://www.jeccr.com/content/27/1/34
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nocytes served as internal positive controls for Glut-1.
Samples of placenta and from gray matter of the cerebral
hemispheres were used as positive controls for Glut-3. For
negative controls, the primary antibodies were omitted.
Sections that had been immunostained for Glut-1 or Glut-
3 were independently assessed by two observers (PP and
GM). Where the results were ambiguous, an agreement
was reached after discussion. The results of the immuno-
histochemical analysis were evaluated according to the
intensity of the staining as follows: 0, absent or barely-
detectable staining; 1, weak staining; 2, moderate stain-
ing; and 3, strong staining. The Glut-1 staining intensity
was considered strong when it was equal to that in red
blood cells in the same sections.
Statistical analysis
Two-tailed Fisher's exact test was used to analyze the con-
tingency tables and P < 0.05 was considered to be statisti-
cally significant. Statistical analyses were performed by
JMP software (SAS Institute Inc., CARY, NC, USA).
Results
The normal keratinizing epithelium in samples from all
the patients showed immunoreactivity for Glut-1 and
Glut-3 in the basal cell and malpighian layers: the signal
for Glut-1 was strong, whereas that for Glut-3 appeared
weak to moderate. The immunoreactivity of Glut-1 was
always strongly intense in erythrocytes, eccrine sweat
glands and the perineurium of small nerve trunks. In con-
trast, the antibody against Glut-3 stained the vascular
endothelium together with a number of dendritic cells
throughout the squamous cell layer. The immunohisto-
chemical results for all the melanocytic lesions are sum-
marized in Table 2. In all the cases studied, staining of
Glut-1 and Glut-3 occurred in both the plasma membrane
and the cytoplasm of the tumour cells. Within the cyto-
plasm, the staining pattern was granular.
Benign lesions
All the melanocytic nevi (12) were positive for both Glut-
1 and Glut-3. Glut-1 immunoreactivity was weak in five
cases, moderate in six cases [Figure 1], and intense in one
case. The immunoreactivity for Glut-3 was weak in one
case, moderate in five cases, and intense in six cases [Fig-
ure 2].
Among the twelve cases of Spitz nevus, positive immunos-
taining for Glut-1 was observed in nine cases. Eight of
these showed weak immunoreactivity [Figure 3], and one
showed moderate immunoreactivity. Only three cases of
Spitz nevi did not show Glut-1 immunoreactivity. Glut-3
expression was evident in all cases, and ten showed strong
expression. Only two cases were weakly positive. There-
fore, nine cases were positive for both Glut-1 and Glut-3.
Overall, among the 24 benign melanocytic lesions, Glut-
1 was expressed in 21 cases (87.5%), and Glut-3 in all
cases (100%).
Malignant melanomas
Of the ten tumours in the group with thickness ≤ 1 mm,
five were positive for the expression of Glut-1, and immu-
noreactivity was not or barely detected in the remaining
five specimens. All ten tumours were positive for Glut-3.
The intensity of staining for Glut-3 was weak in two cases,
moderate in one case, and intense in seven cases. There-
fore, five cases showed the concurrent expression of Glut-
1 and Glut-3.
Of the ten cases in the group with thickness > 1 mm, Glut-
1 immunoreactivity was present in four tumours, with
weak immunoreactivity in three cases and moderate
immunoreactivity in one case. Six tumours did not show
Glut-1 immunoreactivity [Figure 4]. Glut-3 expression
was evident in all tumours, with intense immunoreactiv-
ity in nine cases [Figure 5] and weak immunoreactivity in
one case. Four cases were positive for both Glut-1 and
Glut-3.
Statistical analysis
For statistical purposes, the 44 specimens were catego-
rized in two groups: benign melanocytic lesions, which
comprised melanocytic nevi and Spitz nevi, and malig-
nant melanomas. The results of the statistical analysis
showed that Glut-1 was significantly expressed in benign
lesions as compared to malignant melanomas (p =
0.0118). Conversely, Glut-3 was expressed in all benign
and malignant melanocytic lesions, with no significant
differences. With regard to the malignant melanomas, no
significant correlation was found between Glut-1 expres-
sion and the thickness of the tumour.
Table 2: Immunohistochemical expression of Glut-1 and Glut-3 in benign melanocytic lesions and malignant melanomas
Histological diagnosis Glut-1 expression (%) Glut-3 expression (%)
01 2 3 0 1 2 3
Benign melanocytic lesions
(n = 24)
3(13) 13(54) 7(29) 1(4) 0 3(1) 5(21) 16(67)
Malignant melanoma
(n = 20)
11(55) 8(40) 1(5) 0 0 3(15) 1(5) 16(80)Journal of Experimental & Clinical Cancer Research 2008, 27:34 http://www.jeccr.com/content/27/1/34
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Discussion
Reported data indicate that glucose transporters, in partic-
ular Glut-1, play an important role, although not com-
pletely yet understood, in tumour progression. Glut-1,
whose expression can be induced in cancer cells by onco-
genes, growth factors, interleukin-1, local hypoxia and
inflammatory changes, enhances the activity of the matrix
metalloproteinases, whose activities have been directly
related to tumour invasiveness and metastasis [2,6,9,19].
Several reports indicate that the expression of the glucose
transporters Glut-1 and/or Glut-3 is upregulated in many
neoplasms and correlates with the uptake of the glucose
analogue 18FDG in a variety of human tumours [20-24].
To the best of our knowledge, there have not been any pre-
vious immunohistochemical studies that have success-
fully detected Glut-1 and Glut-3 in melanocytic lesions. In
our study, immunoreactivity of Glut-1 was detected in
100% of the melanocytic nevi, in 75% of the Spitz nevi
and in 45% of the melanomas, whereas Glut-3 was
expressed in all the melanocytic lesions, both benign and
malignant. The proportion of the benign tumours which
expressed Glut-1 was significantly higher than that of the
malignant tumours which were positive for Glut-1. We
also observed that the intensity of immunoreactivity for
Glut-1 was higher in benign lesions than in malignant
ones. These findings suggest that Glut-1 and Glut-3 play a
Glut-1 is not expressed in a malignant melanoma > 1 mm  thick Figure 4
Glut-1 is not expressed in a malignant melanoma > 1 mm 
thick.
Strong immunoreactivity for Glut-3 in a melanocytic nevus Figure 2
Strong immunoreactivity for Glut-3 in a melanocytic nevus.
Melanocytic nevus with moderate staining for Glut-1 Figure 1
Melanocytic nevus with moderate staining for Glut-1.
Spitz nevus showing weak immunoreactivity for Glut-1 Figure 3
Spitz nevus showing weak immunoreactivity for Glut-1.Journal of Experimental & Clinical Cancer Research 2008, 27:34 http://www.jeccr.com/content/27/1/34
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role in the regulation of glucose metabolism in human
melanocytic lesions.
Although Breslow's thickness remains the most important
prognostic factor for cutaneous melanoma, our study has
shown no significant correlation between Glut-1 expres-
sion and the thickness of the tumour [25]. Additional
studies seem to be necessary to confirm the data.
The variation in the immunoreactivity that we obtained in
melanomas is in agreement with the results of the study
by Wachsberger et al, in which a wide variability in Glut-
1 levels as detected by western immunoblotting on
human melanomas was reported [26]. Also, our findings
agree with a number of reports that indicate that meta-
bolic imaging with 18FDG is not a sensitive indicator of
occult metastases in patients with malignant melanoma
[27-30].
The results of our study have significant differences when
compared with those of previous studies, which demon-
strated that Glut-1 is overexpressed in human tumours.
Firstly, most of the published reports studied epithelial
neoplasms, whereas nevi and malignant melanomas arise
from melanocytes, which originate from the neural crest.
It is well known that melanocytes and derived cells
express antigens that are not found in epithelial elements.
Secondly, the tumours previously described in the medi-
cal literature showed variable intratumoural expression of
Glut-1 with an intense immunoreactivity in aggressive
regions of the tumour, such as the poorly differentiated
and central hypoxic areas [9]. However, we observed
homogeneous Glut-1 expression throughout the tumours
examined. In our study, all positive samples (benign and
malignant) showed a membranous and cytoplasmic
immunoreactivity for both Glut-1 and Glut-3, independ-
ent of staining intensity, whereas other researchers have
demonstrated a cytoplasmic and/or membranous staining
pattern [7,11,21]. It should be noted that an increase in
the immunoreactivity of Glut-1 and the membranous
staining pattern have been reported as indicators of
hypoxia [11,31-34]. Finally, the melanomas were much
smaller in volume and had less cellularity than the carci-
nomas, and did not contain any cystic, necrotic or haem-
orrhagic components.
In the medical literature, we have found only one study
that investigated Glut-1 in nevi and melanomas, and the
authors reported that all the melanocytic lesions exam-
ined were negative for Glut-1 expression [18]. These dif-
fering results could be due to the use of a different
antibody. Nevertheless, we are unaware of any previous
study that examined Glut-3 expression in benign and/or
malignant melanocytic lesions.
Conclusion
Our study clearly shows for the first time that Glut-1 is
expressed in all melanocytic nevi and the majority of Spitz
nevi, whereas Glut-1 expression is downregulated in 55%
of malignant melanomas. However, Glut-3 is present in
malignant melanomas as well as in benign lesions. Our
results suggest that human malignant melanomas and
benign nevi show a differential expression of the glucose
transporter Glut-1. Also, these data support the idea that,
in a number of melanomas, other key factors, i.e. other
glucose transporter isoforms, rather Glut-1, or other proc-
esses may contribute to glucose transport across the cell
membrane. However, additional studies needed to further
explore glucose metabolism of melanocytic lesions.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PP conceived of the study, collected the data and drafted
the manuscript. AC designed this study and modified the
manuscript. GM procured reagents, supervised the experi-
mental work and performed microphotography. AM and
MMF carried out the immunohistochemical analyses. GB
participated in the designed of the study, and has been
involved in revising the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We thank F. Federico and F. Castri for help in revising the histological 
slides, and F. Ranelletti for his expert contribution to the statistical analyses.
Strong immunoreactivity for Glut-3 in a malignant melanoma  > 1 mm thick Figure 5
Strong immunoreactivity for Glut-3 in a malignant melanoma 
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